<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20100917112249+02'00'</creation_date><modification_date>D:20100917112251+02'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-04-290_h_dec_10.pdf</pdf_file></head><body><section><header>en  
   en</header></section><section><header>en</header></section><section><header>en  
   en</header><p>european commission brussels, 16.9.2010 c(2010)6440</p></section><section><header>commission decision of 16.9.2010 
 amending the marketing authorisation for &quot;alimta - pemetrexed&quot;, a medicinal 
 product for human use, granted by decision c(2004)3580</header><p>(only the dutch text is authentic)</p></section><section><header>en</header><p>2</p></section><section><header>en</header></section><section><header>commission decision of 16.9.2010 
 amending the marketing authorisation for &quot;alimta - pemetrexed&quot;, a medicinal 
 product for human use, granted by decision c(2004)3580 
 (text with eea relevance)</header><p>the european commission, having regard to the treaty on the functioning of the european union, 
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a 
 european medicines agency
 1, having regard to commission regulation (ec) no 1234/2008 of 24 november 2008 
 concerning the examination of variations to the terms of marketing authorisations for 
 medicinal products for human use and veterinary medicinal products
 2, and in particular article 17(2) thereof, 
 having regard to the notification submitted by eli lilly nederland b.v., under article 
 15(1) of regulation (ec) no 1234/2008, 
 whereas: 
 (1)</p><p>the european medicines agency has informed the marketing authorisation 
 holder and the commission of its favourable opinion on the minor variation of 
 type ib, notified between 11 january 2010 and 1 september 2010, and of the need 
 to amend the decision granting the marketing authorisation. 
 (2)</p><p>the marketing authorisation should be updated and decision c(2004)3580 of 20 
 september 2004 should therefore be amended accordingly. the community 
 register of medicinal products should also be updated. 
 (3)</p><p>for the sake of clarity and transparency, it is appropriate, following the 
 amendment of part or parts of the annexes, to provide for a consolidated version 
 thereof. the annexes to decision c(2004)3580 should therefore be replaced, 
 has adopted this decision: 
 article 1 decision c(2004)3580 is amended as follows:</p><p>
 1 oj l 136, 30.4.2004, p. 1. 2 oj l 334, 12.12.2008, p. 7.</p></section><section><header>en</header><p>3</p></section><section><header>en</header><p>1) the following notification for a minor variation is added to the marketing authorisation: 
 application number 
 scope (eu numbers affected) 
 emea/h/c/564/ib/27 
 b.ii.f.1.b).1 (eu/1/04/290/001)</p><p>
 2) annex i is replaced by the text set out in the annex i to this decision. 
 article 2 this decision is addressed to eli lilly nederland b.v., grootslag 1-5, 3991 ra houten, nederland. 
 done at brussels, on 16.9.2010.</p><p>for the commission</p><p>
 paola testori coggi</p><p>
 director-general</p></section></body></xml>